The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

FDA panel recommends Pfizer?s epoetin alfa biosimilar to treat anemia.....           Harpoon Therapeutics raises $45m in new funding round.....           Merck licenses Teijin Pharma's Alzheimer's candidate.....           AbbVie's ex-U.S. Humira sales are on the precipice. But no need to panic, analysts say.....           Bristol-Myers, leading immuno-oncology in liver cancer, nabs Opdivo 'priority' tag and nears Bayer showdown.....           Johnson & Johnson to pay $33M to resolve allegations of slipshod manufacturing.....           California Lipitor plaintiffs win a chance to argue the Pfizer medication triggered their diabetes.....           Accelerated FDA approval and pricey drugs make a rotten combo, doctors argue.....           Ex-Heritage execs turn state's evidence in far-reaching generic pricing probe.....           FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson.....           Trio of patients sue Pfizer, BMS, claiming they soft-pedaled Eliquis bleeding risks.....           Inovio?s HIV vaccine succeeds in early stage trial.....           Debiopharm acquires ImmunoGen?s ADC IMGN529/Debio 1562.....           Neurocrine?s Ingrezza fails in phase II Tourette syndrome study.....           Novartis adds to biologics manufacturing in midst of global job cutting.....           Sanofi executive lays out case for taxpayer funding?and exclusive licensing?on Zika vaccine R&D.....           First Ocrevus patient comes down with PML?but is the Roche med really to blame?.....           UK?s CMA accuses Merck of breaching competition law.....           FDA approves Merck?s Keytruda for cancer patients with certain biomarkers.....           Tourette was supposed to be Ingrezza's big driver, but a trial flop has forced a detour.....           Pfizer's Epogen biosim scores solid backing from FDA staff ahead of panel review.....           Inovio?s NIH-backed HIV vaccine shows near 100% immune response rate in early test.....           Johnson & Johnson sold us the talc product, Valeant CEO says. Now it should cover our legal defense.....           Which pharma execs win the popularity contest? Roche grabs two top-3 slots, for one.....           Novartis adds to biologics manufacturing in midst of global job cutting.....           First Ocrevus patient comes down with PML?but is the Roche med really to blame?.....           Fresh off two new FDA nods, Merck's high-flying Keytruda nets priority status in stomach cancer.....           Merck's Keytruda wins first FDA nod to treat genetically ID'd tumors anywhere in the body.....           Pfizer bows first Ibrance TV spot as Novartis revs up with rival breast cancer med Kisqali.....           AstraZeneca's Bydureon cleared a heart safety test, but didn't cut risks. Can it still vie with Novo?.....           Merck's Remicade discounting put squeeze on biosims?and broke U.K. law, officials say.....           Alexion's C-suite overhaul continues as CFO, R&D chief exit, new commercial head enters.....           Fresh off two new FDA nods, Merck's high-flying Keytruda nets priority status in stomach cancer.....           Merck's Keytruda picks up a trifecta with FDA approval to treat rare tumor type.....           Recordati to buy AstraZeneca?s European beta-blocker treatments for $300m.....           Nektar, Takeda to explore combination cancer therapy approaches.....           Genentech?s Actemra approved by FDA for giant cell arteritis treatment.....           AZ's Bydureon cleared a heart safety test, but didn't cut risks. Can it still vie with Novo?.....           Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price.....           Merck's Gardasil preps for head-to-head with GlaxoSmithKline?s Cervarix in China, with big sales targets ahead.....           AstraZeneca's controversial castoffs continue with $300M heart-drug sale to Recordati.....           Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug.....           Nevada bill could force Sanofi, Novo and Lilly to reveal their insulin pricing secrets.....           Look out, pharma marketers. California may turn off speaking fees and ban pharma gifts.....           Novo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal' Q1.....           AstraZeneca's new benralizumab helps severe asthma patients cut back on steroids.....           Sanofi, Regeneron set Kevzara up for tough RA turf battle with $39K list price.....           EMA's CHMP backs Novartis' Zykadia for first-line use in lung cancer.....           Iterum Therapeutics raises $65m in new financing round.....           Proteorex, Corbin partner to discover ubiquitin-specific protease inhibitors.....           AZ's controversial castoffs continue with $300M heart-med sale to Recordati.....           Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug.....           Drama and diagnosis on soap opera set troubles cancer doctors, puts Incyte in hot seat.....           Vertex wins once-rejected Kalydeco label expansion, bumping guidance by $30M-plus.....           No scandal here, say rare disease drugmakers, as pricing scrutiny lands on their doorstep.....           FiercePharmaAsia?China?s drug policy overhaul, top generic drugmakers, BI?s China biologics plant.....           J&J fires off legal salvo to block Samsung's Remicade biosim launch.....           The gang's all here: Merck's Keytruda nabs I-O's third bladder cancer approval this month.....           Vertex wins once-rejected Kalydeco label expansion, bumping guidance by $30M-plus.....           European countries offer goodies in bid to win EMA after Brexit.....           Shire?s swelling disorder drug meets primary and secondary endpoints in phase 3 study.....           FDA places clinical hold on Concert Pharmaceuticals? hair loss drug.....           Amgen submits BLA of migraine prevention drug to FDA.....           Teva, ditching a penchant for Israeli execs, taps out-of-towner as lead CEO pick: report.....           ASCO: Merck's Keytruda-chemo combo approach racks up more support with positive overall survival data.....           New study could boost vaccination argument for Merck's Gardasil.....           ASCO: Lilly's abemaciclib vs. Pfizer's Ibrance? Too early to make a call, analysts say.....           Bayer lymphoma candidate secures FDA priority review designation.....           Aduro Biotech expands clinical collaboration with Merck.....           ImmunoGen unveils promising data with mirvetuximab soravtansine in ovarian cancer.....           Sanofi's Zika-shot pricing dust-up highlights a divide over taxpayer-backed vaccine R&D.....           Overwrought marketing? Ads, not research, create some pharma best-sellers.....           Judge limits class-action lawsuit against 'low-T' drugs but lets it head to trial next month.....           Johnson & Johnson's new black-box warning on Invokana could boost its Lilly, AstraZeneca rivals: analyst.....           Merck, Upsher-Smith put ancient K-Dur pay-for-delay case to rest in $60M settlement.....           Key Humira patent goes down via IPR?but biosims makers shouldn't celebrate yet, analysts warn.....           Teva laying off 500 at struggling sterile injectables plant in Hungary.....           EC launches probe into Aspen's pricing practices for cancer drugs.....           Biogen acquires Remedy Pharmaceuticals' stroke drug.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
PharmSci 2017 - first announcement

Tuesday 5 - Thursday 7 September 2017 at De Havilland Campus, University of Hertfordshire, Hatfield

The theme of the conference in 2017 is:
'Pharmaceutical Science without Borders'

The APS is pleased to announce Professor Abdul Basit as this year's Conference Science Chair.

Professor of Pharmaceutics at the School of Pharmacy, University College London, where he leads a research group investigating drug delivery to the gastrointestinal tract.

"I am delighted to be Chairing the 8th APS International PharmSci Conference 2017 at the University of Hertfordshire, where our focus this year is "Pharmaceutical Science without Borders". Pharmaceutical science transcends a multitude of borders - it is very much an international field, collaborative in nature and underpins medicines development. The healthcare challenges we face today are global, and cannot be addressed in isolation. Our aim in this conference is to connect, empower and inspire those of you across the pharmaceutical sciences sector and beyond; to broaden your research goals and horizons alongside showcasing pragmatic approaches to trouble-shooting/problem-solving in the pharmaceutical sciences. I look forward to welcoming you to what will no doubt be a fascinating and intellectually stimulating event."

You can become part of this conference now.

Reserve the date, suggest a topic, offer a poster presentation, reserve an exhibition space and many other opportunities. Please email

Please also regularly check the PharmSci website for updates.

PharmSci 2016 Conference - Chair's review

The Chair of the Academy of Phamaceutical Sciences, Dr Linda Hakes, gives a brief review of the 7th APS International PharmSci Conference, held in Glasgow on 5-7 September 2016.

"2016 has come to an end and although I admit that I am probably biased, I think it was a fantastic three days. The venue, the Technology and Innovation Centre at Strathclyde University, was well equipped to handle the conference and the facilities are modern and efficient.

All of the conference sessions (as far as I could tell) were well attended and the plenary lectures were all excellent, covering topics ranging across the spectrum of pharmaceutical sciences, embracing chemistry, pharmacology, medical devices, formulation, pharmacokinetics and spectroscopy.

A highlight of the social side was the Civic Reception in the City Chambers, a magnificent building on George Square, where we were warmly welcomed by the Bailey Steward on behalf of the Lord Provost of Glasgow.






As always the Black Tie Dinner was a great success and we were pleased to have Prof. Sandy Florence as guest speaker. Again, the venue was truly impressive – the Barony Hall.





To sum up, I believe we enjoyed a conference full of good science, excellent networking opportunities, and highly enjoyable social events. If you weren’t there, why not make a note for next year –
Tuesday 5 - Thursday 7 September 2017 at the University of
Hertfordshire .

See you there!"

Latest News
RPS Excellence in Pharmaceutical Science Excellence in Pharmaceutical Science Award
Excellence in Pharmaceutical Science recognises those who have delivered proactive and innovative projects and initiatives that lead the way in pharmaceutical science. . The nominee should have demonstrated excellence in pharmaceutical science, by showing innovation and initiative, and contributing to a project which has had an impact on the improvement of pharmaceutical science.. To download the nomination form, please visit us online here:. To be considered for the nomination the nominee must cover all aspects in the criteria. Completed nomination forms should be sent to by Monday 29 May 5pm..
Applications invited for the 2017 Royal Pharmaceutical Society Science Award
Applications are invited for the 2017 Royal Pharmaceutical Society Science Award. The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the RPS Award Lecture on their work at the Academy of Pharmaceutical Sciences International PharmSci Conference meeting on Thursday 7th September 2017.. Applications are welcome from scientists world-wide who are working in a pharmaceutical or allied discipline in industry or academia. With up to 10 years experience at post-doctoral level in September 2017, applicants must have a proven record of independent research and published work that shows outstanding promise. . Applicants are invited to submit the following details by 31st May 2017: . · Full CV detailing personal information, past and present appointments, research responsibilities and published work. . · List of research students who have worked for the applicant and their thesis titles and dates, plus any other instances of research collaborations . · Details of research grants awarded and the candidate’s role . · Invitations to speak at conferences in the UK and overseas, lecture or symposium titles and names of awards . · A brief resume of two pages should also be submitted with the CV, indicating discoveries made (please note copies of publications are not required). . Submissions should be sent to: or by post to: Rachel Joynes, Head of Research Royal Pharmaceutical Society 66-68 East Smithfield London E1W 1AW. .
APS 8th International PharmSci Conference 2017 Call for Abstracts
. 'Pharmaceutical Sciences Without Borders’. Tuesday 5 – Thursday 7 September 2017 De Havilland Campus of the University of Hertfordshire in Hatfield. Call for Abstracts. Abstracts are invited for posters for APS International PharmSci 2017. This is one of the most exciting parts of the conference as it represents the presentation of the very latest pharmaceutical science research.. Abstracts on any aspect of the Pharmaceutical Sciences are welcomed and those with a particular emphasis on the theme of this year’s Conference, 'Pharmaceutical Sciences Without Borders’ are particularly appreciated. Details of the various subject categories, an abstract template and details of the entry process can be found here:. Please ensure abstracts are submitted online and comply with the Abstract Submission Template. Please note one or two page abstracts are welcomed providing they follow the template.. There will be prizes awarded for winning posters on each day of the Conference and authors of abstracts of particular interest will be invited to give podium presentations (15min). This is an excellent chance to get your science recognised at the UK’s premier Pharmaceutical Science Conference. The closing date for abstract submission is Friday 17th March 2017.. Abstracts will be made available to Conference registrants when the abstract author has registered for the Conference. We also intend to publish the abstracts in a journal after the Conference and authors not wishing to take up this opportunity are requested to indicate this where indicated when they submit their abstract.. Entrants in the Analytical Chemistry category may be eligible for the Geoffrey Phillips Analytical Science Award, subject to meeting the criteria, awarded by the Joint Pharmaceutical Analysis Group (JPAG). The purpose of the Award is to encourage the advancement of pharmaceutical analysis and to recognise contributions of emerging scientists reporting wholly or mainly their own work. The winner receives a prestigious award with a bursary of up to £1000 to attend a conference relevant to their area of interest.. Exhibitor Opportunities. The conference includes a large pharmaceutical sciences exhibition, which is open to large pharma companies, small and medium size enterprises (SMEs), contract research organisations (CROs) and technology suppliers. With one of the largest gatherings of pharmaceutical scientists in the UK, the conference offers a great opportunity to showcase your company.. For more information please contact us: or 0116 274 7351. .
APS Fellowships Announcement 2017
Do you know someone who has made a significant contribution to Pharmaceutical Science?. The APS is calling for nominations of candidates to become Fellow or Eminent Fellow of the Academy of Pharmaceutical Sciences.. Nominees for Fellowship must be a member of APS (for at least one year) and have a proven track record in pharmaceutical science, as demonstrated by at least 15 peer-reviewed publications, patents or equivalent. This would include significant contributions to the development of products or medical devises within the pharmaceutical industry. Nominees must also have demonstrated leadership and peer recognition through invited lectures, conference leadership, mentoring of young scientists etc. Candidates may self-nominate and nominations must consist of a one-page summary of achievements accompanies by a CV.. Nominations for Eminent Fellowship may be submitted by any member of APS but self-nominations are not accepted. Nominees for Eminent Fellowship must have international recognition for their advocacy of science and have demonstrated leadership at international level. Nominations should consist of a one-page summary of achievements and an explanation of why Eminent Fellowship is justified, and be accompanied by a CV.. Nominations should be sent to by 1 March 2017.
Follow us
Upcoming Events
APS Board and Advisory Board Meeting
12 July 2017
APS 8th International PharmSci Conference 2017
5 - 7 September 2017
APS Advances in Amorphous Design, Control and Delivery of Amorphous and Co-amorphous Pharmaceutical Materials
3 October 2017
APS Clinically relevant dissolution
November 2017
Alternatives to Antibiotics
- joint meeting with the Society for Applied Microbiology

23 November 2017
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.